AcelRx Pharma shares sink as FDA rejects its opioid painkiller

(Reuters) - AcelRx Pharmaceuticals Inc's shares plunged more than 60 percent before the bell on Thursday after the U.S. Food and Drug Administration rejected the drugmaker's opioid painkiller in its present form.